Cargo-delivery platforms for targeted delivery of inhibitor cargos against botulism

Current Topics in Medicinal Chemistry

Volumn 14, Issue 18, 2014, Pages 2081-2093

  Wilson, Brenda A ^a   Ho, Mengfei ^a  

^a UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

Author keywords

Antitoxin; Botulinum neurotoxin; Neuromuscular junction; Paralysis; Passive immunization; Post exposure therapeutics; Single chain antibodies; Synaptic function; Tetanus neurotoxin

Indexed keywords

ACETYLCHOLINE; BOTULINUM ANTISERUM; BOTULINUM TOXIN; BOTULINUM TOXIN A; BOTULINUM TOXIN B; CALCITONIN GENE RELATED PEPTIDE; CELL PENETRATING PEPTIDE; CHOLERA TOXIN; DIPHTHERIA TOXIN; DRUG CARRIER; IMMUNOTOXIN; PSEUDOMONAS EXOTOXIN; SHIGA TOXIN; SNARE PROTEIN; SYNAPTOBREVIN; SYNAPTOSOMAL ASSOCIATED PROTEIN 25; SYNTAXIN; TETANUS TOXIN; VIRUS VECTOR; ANTIDOTE; PEPTIDOMIMETIC AGENT; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY;

ADENO ASSOCIATED VIRUS; ARTICLE; BOTULISM; CENTRAL NERVOUS SYSTEM; CLOSTRIDIUM BOTULINUM; CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG MECHANISM; DRUG STRUCTURE; DRUG TARGETING; DRUG UPTAKE; ENDOSOME; FLACCID PARALYSIS; GENETIC TRANSFECTION; IMMUNOGENICITY; IMMUNOREACTIVITY; MUSCLE ATROPHY; NEUROMUSCULAR SYNAPSE; NEUROTRANSMITTER RELEASE; PASSIVE IMMUNIZATION; POST EXPOSURE PROPHYLAXIS; PROTEIN DEGRADATION; RESPIRATORY FAILURE; RETROGRADE NERVE FIBER TRANSPORT; SPASTIC PARESIS; STRUCTURE ACTIVITY RELATION; VACCINATION; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMICAL STRUCTURE; CHEMISTRY; DRUG EFFECTS; HUMAN; MOTONEURON; PARALYSIS; PATHOLOGY; PROCEDURES; SYNAPTIC TRANSMISSION;

ANIMALS; ANTIDOTES; BOTULINUM ANTITOXIN; BOTULINUM TOXINS; BOTULISM; DRUG DELIVERY SYSTEMS; HUMANS; MODELS, MOLECULAR; MOTOR NEURONS; NEUROMUSCULAR JUNCTION; PARALYSIS; PEPTIDOMIMETICS; SINGLE-CHAIN ANTIBODIES; SYNAPTIC TRANSMISSION;

EID: 84926367463     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/1568026614666141022094517     Document Type: Article

References (159)

1. Fabbri, A.; Travaglione, S.; Falzano, L.; Fiorentini, C. Bacterial protein toxins: Current and potential clinical use. Curr. Med. Chem., 2008, 15 (11), 1116-25.
2. Kostrzewa, R.M.; Segura-Aguilar, J. Botulinum neurotoxin: Evolution from poison, to research tool--onto medicinal therapeutic and future pharmaceutical panacea. Neurotox Res., 2007, 12 (4), 275-90.
3. Lemonnier, M.; Landraud, L.; Lemichez, E. Rho GTPaseactivating bacterial toxins: From bacterial virulence regulation to eukaryotic cell biology. FEMS Microbiol Rev., 2007, 31 (5), 515-34.
4. Sandvig, K.; Torgersen, M.L.; Engedal, N.; Skotland, T.; Iversen, T.G. Protein toxins from plants and bacteria: Probes for intracellular transport and tools in medicine. FEBS Lett., 2010, 584 (12), 2626-34.
5. Schiavo, G.; van der Goot, F.G. The bacterial toxin toolkit. Nat. Rev. Mol. Cell Biol., 2001, 2 (7), 530-7.
6. Weidle, U.H.; Tiefenthaler, G.; Schiller, C.; Weiss, E.H.; Georges, G.; Brinkmann, U. Prospects of bacterial and plant protein-based immunotoxins for treatment of cancer. Cancer Genom. Pro., 2014, 11 (1), 25-38.
7. Wilson, B.A.; Ho, M. Pasteurella multocida toxin as a tool for studying Gq signal transduction. Rev. Physiol. Biochem. Pharma., 2004, 152, 93-109.
8. Wilson, B.A.; Ho, M. Recent insights into Pasteurella multocida toxin and other G-protein-modulating bacterial toxins. Fut. Microbiol., 2010, 5 (8), 1185-201.
9. Aoki, K.R.; Smith, L.A.; Atassi, M.Z. Mode of action of botulinum neurotoxins: Current vaccination strategies and molecular immune recognition. Crit. Rev. Immunol., 2010, 30 (2), 167-87.
10. Henkel, J.S.; Tepp, W.H.; Przedpelski, A.; Fritz, R.B.; Johnson, E.A.; Barbieri, J.T. Subunit vaccine efficacy against botulinum neurotoxin subtypes. Vaccine, 2011, 29 (44), 7688-95.
11. Hill, S.E.; Iqbal, R.; Cadiz, C.L.; Le, J. Foodborne botulism treated with heptavalent botulism antitoxin. Ann Pharmacother., 2013, 47 (2), e12.
12. Ramasamy, S.; Liu, C.Q.; Tran, H.; Gubala, A.; Gauci, P.; McAllister, J.; Vo, T. Principles of antidote pharmacology: An update on prophylaxis, post-exposure treatment recommendations and research initiatives for biological agents. Br. J. Pharmacol., 2010, 161 (4), 721-48.
13. Schneemann, A.; Manchester, M. Anti-toxin antibodies in prophylaxis and treatment of inhalation anthrax. Fut. Microbiol., 2009, 4 (1), 35-43.
14. Popoff, M.R. Botulinum neurotoxins: More and more diverse and fascinating toxic proteins. J. Infect. Dis., 2014, 209 (2), 168-9.
15. Popoff, M.R.; Bouvet, P. Genetic characteristics of toxigenic Clostridia and toxin gene evolution. Toxicon, 2013, 75, 63-89.
16. Gu, S.; Jin, R. Assembly and function of the botulinum neurotoxin progenitor complex. Curr. Top. Microbiol. Immunol., 2013, 364, 21-44.
17. Couesnon, A.; Molgo, J.; Connan, C.; Popoff, M.R. Preferential entry of botulinum neurotoxin A Hc domain through intestinal crypt cells and targeting to cholinergic neurons of the mouse intestine. PLoS Pathog, 2012, 8 (3), e1002583.
18. Fujii, N.; Kimura, K.; Yashiki, T.; Tsuzuki, K.; Moriishi, K.; Yokosawa, N.; Syuto, B.; Oguma, K. Cloning and whole nucleotide sequence of the gene for the light chain component of botulinum type E toxin from Clostridium butyricum strain BL6340 and Clostridium botulinum type E strain Mashike. Microbiol. Immunol., 1992, 36 (3), 213-20.
19. Lalli, G.; Herreros, J.; Osborne, S.L.; Montecucco, C.; Rossetto, O.; Schiavo, G. Functional characterisation of tetanus and botulinum neurotoxins binding domains. J. Cell Sci., 1999, 112 ( Pt 16), 2715-24.
20. Lacy, D.B.; Tepp, W.; Cohen, A.C.; DasGupta, B.R.; Stevens, R.C. Crystal structure of botulinum neurotoxin type A and implications for toxicity. Nat. Struct. Biol., 1998, 5 (10), 898-902.
21. Swaminathan, S.; Eswaramoorthy, S. Structural analysis of the catalytic and binding sites of Clostridium botulinum neurotoxin B. Nat. Struct. Biol., 2000, 7 (8), 693-9.
22. Kumaran, D.; Eswaramoorthy, S.; Furey, W.; Navaza, J.; Sax, M.; Swaminathan, S. Domain organization in Clostridium botulinum neurotoxin type E is unique: Its implication in faster translocation. J. Mol. Biol., 2009, 386 (1), 233-45.
23. Swaminathan, S. Molecular structures and functional relationships in clostridial neurotoxins. FEBS J., 2011, 278 (23), 4467-85.
24. Lacy, D.B.; Stevens, R.C. Unraveling the structures and modes of action of bacterial toxins. Curr. Opin. Struct. Biol., 1998, 8 (6), 778-84.
25. Montal, M. Translocation of botulinum neurotoxin light chain protease by the heavy chain protein-conducting channel. Toxicon., 2009, 54 (5), 565-9.
26. Montal, M. Botulinum neurotoxin: A marvel of protein design. Annu. Rev. Biochem., 2010, 79, 591-617.
27. Montecucco, C.; Schiavo, G., Mechanism of action of tetanus and botulinum neurotoxins. Mol. Microbiol., 1994, 13 (1), 1-8.
28. Schiavo, G.; Matteoli, M.; Montecucco, C. Neurotoxins affecting neuroexocytosis. Physiological Rev., 2000, 80 (2), 717-66.
29. Schiavo, G.; Rossetto, O.; Benfenati, F.; Poulain, B.; Montecucco, C. Tetanus and botulinum neurotoxins are zinc proteases specific for components of the neuroexocytosis apparatus. Ann. N Y Acad. Sci., 1994, 710, 65-75.
30. Barash, J.R.; Arnon, S.S. A novel strain of Clostridium botulinum that produces type B and type H botulinum toxins. J. Infect Dis., 2014, 209 (2), 183-91.
31. Dover, N.; Barash, J.R.; Hill, K.K.; Xie, G.; Arnon, S.S. Molecular characterization of a novel botulinum neurotoxin type H gene. J. Infect. Dis., 2014, 209 (2), 192-202.
32. Rossetto, O.; Megighian, A.; Scorzeto, M.; Montecucco, C. Botulinum neurotoxins. Toxicon, 2013, 67, 31-6.
33. Bercsenyi, K.; Giribaldi, F.; Schiavo, G. The elusive compass of clostridial neurotoxins: Deciding when and where to go? Curr. Top. Microbiol. Immunol., 2013, 364, 91-113.
34. Rummel, A. Double receptor anchorage of botulinum neurotoxins accounts for their exquisite neurospecificity. Curr. Top. Microbiol. Immunol., 2013, 364, 61-90.
35. Montecucco, C.; Rossetto, O.; Schiavo, G. Presynaptic receptor arrays for clostridial neurotoxins. Trends Microbiol., 2004, 12 (10), 442-6.
36. Simpson, L.L. Identification of the major steps in botulinum toxin action. Annu. Rev. Pharmacol. Toxicol., 2004, 44, 167-93.
37. Arnon, S.S.; Schechter, R.; Inglesby, T.V.; Henderson, D.A.; Bartlett, J.G.; Ascher, M.S.; Eitzen, E.; Fine, A.D.; Hauer, J.; Layton, M.; Lillibridge, S.; Osterholm, M.T.; O'Toole, T.; Parker, G.; Perl, T.M.; Russell, P.K.; Swerdlow, D.L.; Tonat, K.; Working Group on Civilian, B., Botulinum toxin as a biological weapon: Medical and public health management. JAMA, 2001, 285 (8), 1059-70.
38. Simpson, L. The life history of a botulinum toxin molecule. Toxicon, 2013, 68, 40-59.
39. Montecucco, C.; Molgo, J. Botulinal neurotoxins: Revival of an old killer. Curr. Opin. Pharmacol., 2005, 5 (3), 274-9.
40. Humeau, Y.; Doussau, F.; Grant, N.J.; Poulain, B. How botulinum and tetanus neurotoxins block neurotransmitter release. Biochimie., 2000, 82 (5), 427-46.
41. Shoemaker, C.B.; Oyler, G.A. Persistence of Botulinum neurotoxin inactivation of nerve function. Curr. Top. Microbiol. Immunol., 2013, 364, 179-96.
42. Eleopra, R.; Tugnoli, V.; Rossetto, O.; De Grandis, D.; Montecucco, C. Different time courses of recovery after poisoning with botulinum neurotoxin serotypes A and E in humans. Neurosci. Lett., 1998, 256 (3), 135-8.
43. Foran, P.G.; Davletov, B.; Meunier, F.A. Getting muscles moving again after botulinum toxin: Novel therapeutic challenges. Trends mole. med., 2003, 9 (7), 291-9.
44. Meunier, F.A.; Lisk, G.; Sesardic, D.; Dolly, J.O. Dynamics of motor nerve terminal remodeling unveiled using SNARE-cleaving botulinum toxins: The extent and duration are dictated by the sites of SNAP-25 truncation. Mol. Cell Neurosci., 2003, 22 (4), 454-66.
45. Meunier, F.A.; Schiavo, G.; Molgo, J. Botulinum neurotoxins: From paralysis to recovery of functional neuromuscular transmission. J. Physiol. Paris, 2002, 96 (1-2), 105-13.
46. de Paiva, A.; Meunier, F.A.; Molgo, J.; Aoki, K.R.; Dolly, J.O. Functional repair of motor endplates after botulinum neurotoxin type A poisoning: Biphasic switch of synaptic activity between nerve sprouts and their parent terminals. Proc. Natl. Acad. Sci. USA, 1999, 96 (6), 3200-5.
47. Peng, L.; Liu, H.; Ruan, H.; Tepp, W.H.; Stoothoff, W.H.; Brown, R.H.; Johnson, E.A.; Yao, W.D.; Zhang, S.C.; Dong, M. Cytotoxicity of botulinum neurotoxins reveals a direct role of syntaxin 1 and SNAP-25 in neuron survival. Nat. Commun., 2013, 4, 1472.
48. Williamson, L.C.; Neale, E.A. Syntaxin and 25-kDa synaptosomalassociated protein: Differential effects of botulinum neurotoxins C1 and A on neuronal survival. J. Neurosci. Res., 1998, 52 (5), 569-83.
49. Chen, S. Clinical uses of botulinum neurotoxins: Current indications, limitations and future developments. Toxins (Basel), 2012, 4 (10), 913-39.
50. Dolly, J.O.; O'Connell, M.A. Neurotherapeutics to inhibit exocytosis from sensory neurons for the control of chronic pain. Curr. Opin. Pharmacol., 2012, 12 (1), 100-8.
51. Ratanji, K.D.; Derrick, J.P.; Dearman, R.J.; Kimber, I. Immunogenicity of therapeutic proteins: Influence of aggregation. J. Immunotoxicol., 2014, 11 (2), 99-109.
52. Shankar, G.; Pendley, C.; Stein, K.E. A risk-based bioanalytical strategy for the assessment of antibody immune responses against biological drugs. Nat. Biotechnol., 2007, 25 (5), 555-61.
53. Naumann, M.; Boo, L.M.; Ackerman, A.H.; Gallagher, C.J. Immunogenicity of botulinum toxins. J. Neural. Transm., 2013, 120 (2), 275-90.
54. Almagro, J.C.; Fransson, J. Humanization of antibodies. Front Biosci., 2008, 13, 1619-33.
55. Harding, F.A.; Stickler, M.M.; Razo, J.; DuBridge, R.B. The immunogenicity of humanized and fully human antibodies: Residual immunogenicity resides in the CDR regions. MABS, 2010, 2 (3), 256-65.
56. Nagata, S.; Pastan, I. Removal of B cell epitopes as a practical approach for reducing the immunogenicity of foreign protein-based therapeutics. Adv. Drug Deliv. Rev., 2009, 61 (11), 977-85.
57. Antignani, A.; Fitzgerald, D. Immunotoxins: The role of the toxin. Toxins (Basel), 2013, 5 (8), 1486-502.
58. Thorpe, P.E.; Ross, W.C. The preparation and cytotoxic properties of antibody-toxin conjugates. Immunol. Rev., 1982, 62, 119-58.
59. Chaudhary, V.K.; Queen, C.; Junghans, R.P.; Waldmann, T.A.; FitzGerald, D.J.; Pastan, I.A recombinant immunotoxin consisting of two antibody variable domains fused to Pseudomonas exotoxin. Nature, 1989, 339 (6223), 394-7.
60. Strom, T.B.; Kelley, V.R.; Woodworth, T.G.; Murphy, J.R., Interleukin-2 receptor-directed immunosuppressive therapies: Antibody-or cytokine-based targeting molecules. Immunol. Rev., 1992, 129, 131-63.
61. Bachran, C.; Morley, T.; Abdelazim, S.; Fattah, R.J.; Liu, S.; Leppla, S.H. Anthrax toxin-mediated delivery of the Pseudomonas exotoxin A enzymatic domain to the cytosol of tumor cells via cleavable ubiquitin fusions. MBIO, 2013, 4 (3), e00201-13.
62. Barth, H.; Aktories, K. New insights into the mode of action of the actin ADP-ribosylating virulence factors Salmonella enterica SpvB and Clostridium botulinum C2 toxin. Eur. J. Cell Biol., 2011, 90 (11), 944-50.
63. De Meyer, T.; Muyldermans, S.; Depicker, A. Nanobody-based products as research and diagnostic tools. Trends Biotechnol., 2014, 32 (5), 263-270.
64. Pastan, I.; Hassan, R. Discovery of mesothelin and exploiting it as a target for immunotherapy. Cancer Res., 2014.
65. Pastan, I.; Hassan, R.; FitzGerald, D.J.; Kreitman, R.J. Immunotoxin treatment of cancer. Annu. Rev. Med., 2007, 58, 221-37.
66. Wayne, A.S.; Fitzgerald, D.J.; Kreitman, R.J.; Pastan, I. Immunotoxins for leukemia. Blood, 2014, 123 (16), 2470-7.
67. Weldon, J.E.; Xiang, L.; Zhang, J.; Beers, R.; Walker, D.A.; Onda, M.; Hassan, R.; Pastan, I. A recombinant immunotoxin against the tumor-associated antigen mesothelin reengineered for high activity, low off-target toxicity, and reduced antigenicity. Mol. Cancer Ther., 2013, 12 (1), 48-57.
68. Benecke, R. Clinical relevance of botulinum toxin immunogenicity. Bio. Drugs, 2012, 26 (2), e1-9.
69. Dressler, D. Clinical applications of botulinum toxin. Curr. Opin. Microbiol., 2012, 15 (3), 325-36.
70. Dressler, D. Five-year experience with incobotulinumtoxinA (Xeomin®): The first botulinum toxin drug free of complexing proteins. Eur. J. Neurol., 2012, 19 (3), 385-9.
71. Dressler, D.; Paus, S.; Seitzinger, A.; Gebhardt, B.; Kupsch, A. Long-term efficacy and safety of incobotulinumtoxinA injections in patients with cervical dystonia. J. Neurol. Neurosurg. Psychiatry, 2013, 84 (9), 1014-9.
72. Masuyer, G.; Chaddock, J.A.; Foster, K.A.; Acharya, K.R. Engineered botulinum neurotoxins as new therapeutics. Annu. Rev. Pharmacol. Toxicol., 2014, 54, 27-51.
73. Stancombe, P.R.; Masuyer, G.; Birch-Machin, I.; Beard, M.; Foster, K.A.; Chaddock, J.A.; Acharya, K.R. Engineering botulinum neurotoxin domains for activation by toxin light chain. J. FEBS, 2012, 279 (3), 515-23.
74. Meng, J.; Ovsepian, S.V.; Wang, J.; Pickering, M.; Sasse, A.; Aoki, K.R.; Lawrence, G.W.; Dolly, J.O. Activation of TRPV1 mediates calcitonin gene-related peptide release, which excites trigeminal sensory neurons and is attenuated by a retargeted botulinum toxin with anti-nociceptive potential. J. Neurosci., 2009, 29 (15), 4981-92.
75. Byrne, M.P.; Smith, L.A. Development of vaccines for prevention of botulism. Biochimie., 2000, 82 (9-10), 955-66.
76. Sobel, J. Botulism. Clin. Infect. Dis., 2005, 41 (8), 1167-73.
77. Arnon, S.S.; Schechter, R.; Maslanka, S.E.; Jewell, N.P.; Hatheway, C.L. Human botulism immune globulin for the treatment of infant botulism. N. Engl. J. Med., 2006, 354 (5), 462-71.
78. Horowitz, B.Z. Botulinum toxin. Crit. Care Clin., 2005, 21 (4), 825-39, viii.
79. Baghban, R.; Gargari, S.L.; Rajabibazl, M.; Nazarian, S.; Bakherad, H. Camelid-derived heavy chain nanobody against Clostridium botulinum neurotoxin E in Pichia pastoris. Biotechnol. Appl. Biochem., 2013, 18(6), 726-35.
80. Bakherad, H.; Mousavi Gargari, S.L.; Rasooli, I.; Rajabibazl, M.; Mohammadi, M.; Ebrahimizadeh, W.; Safaee Ardakani, L.; Zare, H. In vivo neutralization of botulinum neurotoxins serotype E with heavy-chain camelid antibodies (VHH). Mol. Biotechnol., 2013, 55 (2), 159-67.
81. Mukherjee, J.; Tremblay, J.M.; Leysath, C.E.; Ofori, K.; Baldwin, K.; Feng, X.; Bedenice, D.; Webb, R.P.; Wright, P.M.; Smith, L.A.; Tzipori, S.; Shoemaker, C.B. A novel strategy for development of recombinant antitoxin therapeutics tested in a mouse botulism model. PLoS One, 2012, 7 (1), e29941.
82. Foran, P.G.; Mohammed, N.; Lisk, G.O.; Nagwaney, S.; Lawrence, G.W.; Johnson, E.; Smith, L.; Aoki, K.R.; Dolly, J.O. Evaluation of the therapeutic usefulness of botulinum neurotoxin B, C1, E, and F compared with the long lasting type A. Basis for distinct durations of inhibition of exocytosis in central neurons. J. Biol. Chem., 2003, 278 (2), 1363-71.
83. Chertow, D.S.; Tan, E.T.; Maslanka, S.E.; Schulte, J.; Bresnitz, E.A.; Weisman, R.S.; Bernstein, J.; Marcus, S.M.; Kumar, S.; Malecki, J.; Sobel, J.; Braden, C.R. Botulism in 4 adults following cosmetic injections with an unlicensed, highly concentrated botulinum preparation. JAMA, 2006, 296 (20), 2476-9.
84. Bartels, F.; Bergel, H.; Bigalke, H.; Frevert, J.; Halpern, J.; Middlebrook, J. Specific antibodies against the Zn(2+)-binding domain of clostridial neurotoxins restore exocytosis in chromaffin cells treated with tetanus or botulinum A neurotoxin. J. Biol. Chem., 1994, 269 (11), 8122-7.
85. Caglic, D.; Krutein, M.C.; Bompiani, K.M.; Barlow, D.J.; Benoni, G.; Pelletier, J.C.; Reitz, A.B.; Lairson, L.L.; Houseknecht, K.L.; Smith, G.R.; Dickerson, T.J. Identification of clinically viable quinolinol inhibitors of botulinum neurotoxin A light chain. J. Med. Chem., 2014, 57 (3), 669-76.
86. Eubanks, L.M.; Hixon, M.S.; Jin, W.; Hong, S.; Clancy, C.M.; Tepp, W.H.; Baldwin, M.R.; Malizio, C.J.; Goodnough, M.C.; Barbieri, J.T.; Johnson, E.A.; Boger, D.L.; Dickerson, T.J.; Janda, K.D. An in vitro and in vivo disconnect uncovered through high throughput identification of botulinum neurotoxin A antagonists. Proc. Natl. Acad. Sci. U S A, 2007, 104 (8), 2602-7.
87. Pang, Y.P.; Davis, J.; Wang, S.; Park, J.G.; Nambiar, M.P.; Schmidt, J.J.; Millard, C.B. Small molecules showing significant protection of mice against botulinum neurotoxin serotype A. PLoS One, 2010, 5 (4), e10129.
88. Ruthel, G.; Burnett, J.C.; Nuss, J.E.; Wanner, L.M.; Tressler, L.E.; Torres-Melendez, E.; Sandwick, S.J.; Retterer, C.J.; Bavari, S. Post-intoxication inhibition of botulinum neurotoxin serotype A within neurons by small-molecule, non-peptidic inhibitors. Toxins (Basel), 2011, 3 (3), 207-17.
89. Silhar, P.; Silvaggi, N.R.; Pellett, S.; Capkova, K.; Johnson, E.A.; Allen, K.N.; Janda, K.D. Evaluation of adamantane hydroxamates as botulinum neurotoxin inhibitors: Synthesis, crystallography, modeling, kinetic and cellular based studies. Bioorg. Med. Chem., 2013, 21 (5), 1344-8.
90. Capek, P.; Zhang, Y.; Barlow, D.J.; Houseknecht, K.L.; Smith, G.R.; Dickerson, T.J. Enhancing the pharmacokinetic properties of botulinum neurotoxin serotype A protease inhibitors through rational design. ACS Chem. Neurosci., 2011, 2 (6), 288-293.
91. Smith, G.R.; Caglic, D.; Capek, P.; Zhang, Y.; Godbole, S.; Reitz, A.B.; Dickerson, T.J. Reexamining hydroxamate inhibitors of botulinum neurotoxin serotype A: Extending towards the betaexosite. Bioorg. Med. Chem., Lett., 2012, 22 (11), 3754-7.
92. Schmidt, J.J.; Stafford, R.G.; Bostian, K.A. Type A botulinum neurotoxin proteolytic activity: Development of competitive inhibitors and implications for substrate specificity at the S1' binding subsite. FEBS Lett., 1998, 435 (1), 61-4.
93. Silvaggi, N.R.; Wilson, D.; Tzipori, S.; Allen, K.N. Catalytic features of the botulinum neurotoxin A light chain revealed by high resolution structure of an inhibitory peptide complex. Biochemistry, 2008, 47 (21), 5736-45.
94. Hale, M.; Oyler, G.; Swaminathan, S.; Ahmed, S.A. Basic tetrapeptides as potent intracellular inhibitors of type A botulinum neurotoxin protease activity. J. Biol. Chem., 2011, 286 (3), 1802-11.
95. Schmidt, J.J.; Stafford, R.G. A high-affinity competitive inhibitor of type A botulinum neurotoxin protease activity. FEBS Lett., 2002, 532 (3), 423-6.
96. Kumaran, D.; Rawat, R.; Ludivico, M.L.; Ahmed, S.A.; Swaminathan, S. Structure-and substrate-based inhibitor design for Clostridium botulinum neurotoxin serotype A. J. Biol. Chem., 2008, 283 (27), 18883-91.
97. Kumar, G.; Kumaran, D.; Ahmed, S.A.; Swaminathan, S. Peptide inhibitors of botulinum neurotoxin serotype A: Design, inhibition, cocrystal structures, structure-activity relationship and pharmacophore modeling. Acta Crystallogr. D. Biol. Crystallogr., 2012, 68 (Pt 5), 511-20.
98. Agarwal, R.; Schmidt, J.J.; Stafford, R.G.; Swaminathan, S. Mode of VAMP substrate recognition and inhibition of Clostridium botulinum neurotoxin F. Nat. Struct. Mol. Biol., 2009, 16 (7), 789-94.
99. Schmidt, J.J.; Stafford, R.G. Botulinum neurotoxin serotype F: Identification of substrate recognition requirements and development of inhibitors with low nanomolar affinity. Biochemistry, 2005, 44 (10), 4067-73.
100. [100] Zuniga, J.E.; Schmidt, J.J.; Fenn, T.; Burnett, J.C.; Arac, D.; Gussio, R.; Stafford, R.G.; Badie, S.S.; Bavari, S.; Brunger, A.T. A potent peptidomimetic inhibitor of botulinum neurotoxin serotype A has a very different conformation than SNAP-25 substrate. Structure, 2008, 16 (10), 1588-97.
101. [101] Chen, S.; Barbieri, J.T. Unique substrate recognition by botulinum neurotoxins serotypes A and E. J. Biol. Chem., 2006, 281 (16), 10906-11.
102. [102] O'Sullivan, G.A.; Mohammed, N.; Foran, P.G.; Lawrence, G.W.; Oliver Dolly, J. Rescue of exocytosis in botulinum toxin Apoisoned chromaffin cells by expression of cleavage-resistant SNAP-25. Identification of the minimal essential C-terminal residues. J. Biol. Chem., 1999, 274 (52), 36897-904.
103. [103] Raghunath, A.; Perez-Branguli, F.; Smith, L.; Dolly, J.O. Adenoassociated virus transfer of a gene encoding SNAP-25 resistant to botulinum toxin A attenuates neuromuscular paralysis associated with botulism. J. Neurosci., 2008, 28 (14), 3683-8.
104. [104] Ho, M.; Goh, C.H.; Brothers, M.C.; Wang, S.; Young, R.L.; Ou, Y.; Lui, J.N.; Kalafatis, M.; Lan, X.; Wolf, A.E.; Rienstra, C.M.; Wilson, B.A. Glycine insertion at protease cleavage site of SNAP25 resists cleavage but enhances affinity for botulinum neurotoxin serotype A. Protein. Sci., 2012, 21 (3), 318-26.
105. [105] Tremblay, J.M.; Kuo, C.L.; Abeijon, C.; Sepulveda, J.; Oyler, G.; Hu, X.; Jin, M.M.; Shoemaker, C.B. Camelid single domain antibodies (VHHs) as neuronal cell intrabody binding agents and inhibitors of Clostridium botulinum neurotoxin (BoNT) proteases. Toxicon, 2010, 56 (6), 990-8.
106. [106] Dong, J.; Thompson, A.A.; Fan, Y.; Lou, J.; Conrad, F.; Ho, M.; Pires-Alves, M.; Wilson, B.A.; Stevens, R.C.; Marks, J.D. A single-domain llama antibody potently inhibits the enzymatic activity of botulinum neurotoxin by binding to the non-catalytic alpha-exosite binding region. J. Mol. Biol., 2010, 397 (4), 1106-18.
107. [107] Thanongsaksrikul, J.; Srimanote, P.; Maneewatch, S.; Choowongkomon, K.; Tapchaisri, P.; Makino, S.; Kurazono, H.; Chaicumpa, W. A V H H that neutralizes the zinc metalloproteinase activity of botulinum neurotoxin type A. J. Biol. Chem., 2010, 285 (13), 9657-66.
108. [108] Adekar, S.P.; Takahashi, T.; Jones, R.M.; Al-Saleem, F.H.; Ancharski, D.M.; Root, M.J.; Kapadnis, B.P.; Simpson, L.L.; Dessain, S.K. Neutralization of botulinum neurotoxin by a human monoclonal antibody specific for the catalytic light chain. PLoS One, 2008, 3 (8), e3023.
109. [109] O'Leary, V.B.; Ovsepian, S.V.; Raghunath, A.; Huo, Q.; Lawrence, G.W.; Smith, L.; Dolly, J.O. Innocuous full-length botulinum neurotoxin targets and promotes the expression of lentiviral vectors in central and autonomic neurons. Gene. Ther., 2011, 18 (7), 656-65.
110. [110] Tsai, Y.C.; Maditz, R.; Kuo, C.L.; Fishman, P.S.; Shoemaker, C.B.; Oyler, G.A.; Weissman, A.M. Targeting botulinum neurotoxin persistence by the ubiquitin-proteasome system. Proc. Natl. Acad. Sci. U S A, 2010, 107 (38), 16554-9.
111. [111] Kuo, C.L.; Oyler, G.A.; Shoemaker, C.B. Accelerated neuronal cell recovery from botulinum neurotoxin intoxication by targeted ubiquitination. PLoS One, 2011, 6 (5), e20352.
112. [112] Toivonen, J.M.; Olivan, S.; Osta, R. Tetanus toxin C-fragment: The courier and the cure? Toxins (Basel), 2010, 2 (11), 2622-44.
113. [113] Coen, L.; Osta, R.; Maury, M.; Brulet, P. Construction of hybrid proteins that migrate retrogradely and transynaptically into the central nervous system. Proc. Natl. Acad. Sci. U S A, 1997, 94 (17), 9400-5.
114. [114] Kissa, K.; Mordelet, E.; Soudais, C.; Kremer, E.J.; Demeneix, B.A.; Brulet, P.; Coen, L. In vivo neuronal tracing with GFP-TTC gene delivery. Mol. Cell Neurosci., 2002, 20 (4), 627-37.
115. [115] Roux, S.; Colasante, C.; Saint Cloment, C.; Barbier, J.; Curie, T.; Girard, E.; Molgo, J.; Brulet, P. Internalization of a GFP-tetanus toxin C-terminal fragment fusion protein at mature mouse neuromuscular junctions. Mol. Cell Neurosci., 2005, 30 (4), 572-82.
116. [116] Carlton, E.; Teng, Q.; Federici, T.; Yang, J.; Riley, J.; Boulis, N.M. Fusion of the tetanus toxin C fragment binding domain and Bcl-xL for protection of peripheral nerve neurons. Neurosurgery, 2008, 63 (6), 1175-82; discussion 1182-4.
117. [117] Calvo, A.C.; Moreno-Igoa, M.; Mancuso, R.; Manzano, R.; Olivan, S.; Munoz, M.J.; Penas, C.; Zaragoza, P.; Navarro, X.; Osta, R. Lack of a synergistic effect of a non-viral ALS gene therapy based on BDNF and a TTC fusion molecule. Orphanet. J. Rare. Dis., 2011, 6, 10.
118. [118] Li, J.; Chian, R.J.; Ay, I.; Kashi, B.B.; Celia, S.A.; Tamrazian, E.; Pepinsky, R.B.; Fishman, P.S.; Brown, R.H. Jr.; Francis, J.W. Insect GDNF:TTC fusion protein improves delivery of GDNF to mouse CNS. Biochem. Biophys. Res. Commun., 2009, 390 (3), 947-51.
119. [119] Cubi, R.; Candalija, A.; Ortega, A.; Gil, C.; Aguilera, J. Tetanus Toxin Hc fragment induces the formation of ceramide platforms and protects neuronal cells against oxidative stress. PLoS One, 2013, 8 (6), e68055.
120. [120] Andreu, A.; Fairweather, N.; Miller, A.D. Clostridium neurotoxin fragments as potential targeting moieties for liposomal gene delivery to the CNS. Chem. Bio. Chem., 2008, 9 (2), 219-31.
121. [121] Balazs, D.A.; Godbey, W. Liposomes for use in gene delivery. J. Drug Deliv., 2011, 2011, 326497.
122. [122] Frankel, A.D.; Pabo, C.O. Cellular uptake of the tat protein from human immunodeficiency virus. Cell, 1988, 55 (6), 1189-93.
123. [123] Bechara, C.; Sagan, S. Cell-penetrating peptides: 20 years later, where do we stand? FEBS Lett., 2013, 587 (12), 1693-702.
124. [124] Copolovici, D.M.; Langel, K.; Eriste, E.; Langel, U. Cellpenetrating peptides: Design, synthesis and applications. ACS NANO, 2014, 8 (3), 1972-1994.
125. [125] Heitz, F.; Morris, M.C.; Divita, G. Twenty years of cell-penetrating peptides: From molecular mechanisms to therapeutics. Br. J. Pharmacol., 2009, 157 (2), 195-206.
126. [126] Poungpair, O.; Pootong, A.; Maneewatch, S.; Srimanote, P.; Tongtawe, P.; Songserm, T.; Tapchaisri, P.; Chaicumpa, W. A human single chain transbody specific to matrix protein (M1) interferes with the replication of influenza A virus. Bioconjug. Chem., 2010, 21 (7), 1134-41.
127. [127] Thuengin, K.; Thanongsaksrikul, J.; Srimanote, P.; Bangphoomi, K.; Poungpair, O.; Maneewatch, S.; Choowongkomon, K.; Chaicumpa, W. Cell penetrable humanized-VH/V(H)H that inhibit RNA dependent RNA polymerase (NS5B) of HCV. PLoS One, 2012, 7 (11), e49254.
128. [128] Bade, S.; Rummel, A.; Reisinger, C.; Karnath, T.; Ahnert-Hilger, G.; Bigalke, H.; Binz, T. Botulinum neurotoxin type D enables cytosolic delivery of enzymatically active cargo proteins to neurones via unfolded translocation intermediates. J. Neuro. Chem., 2004, 91 (6), 1461-72.
129. [129] Fischer, A.; Montal, M. Molecular dissection of botulinum neurotoxin reveals interdomain chaperone function. Toxicon, 2013, 75, 101-7.
130. [130] Wang, J.; Zurawski, T.H.; Meng, J.; Lawrence, G.; Olango, W.M.; Finn, D.P.; Wheeler, L.; Dolly, J.O. A dileucine in the protease of botulinum toxin A underlies its long-lived neuroparalysis: Transfer of longevity to a novel potential therapeutic. J. Biol. Chem., 2011,286 (8), 6375-85.
131. [131] Breidenbach, M.A.; Brunger, A.T. Substrate recognition strategy for botulinum neurotoxin serotype A. Nature, 2004, 432 (7019), 925-9.
132. [132] Pier, C.L.; Tepp, W.H.; Bradshaw, M.; Johnson, E.A.; Barbieri, J.T.; Baldwin, M.R. Recombinant holotoxoid vaccine against botulism. Infect. Immun., 2008, 76 (1), 437-42.
133. [133] Webb, R.P.; Smith, T.J.; Wright, P.; Brown, J.; Smith, L.A. Production of catalytically inactive BoNT/A1 holoprotein and comparison with BoNT/A1 subunit vaccines against toxin subtypes A1, A2, and A3. Vaccine, 2009, 27 (33), 4490-7.
134. [134] O'Leary, V.B.; Ovsepian, S.V.; Bodeker, M.; Dolly, J.O. Improved lentiviral transduction of ALS motoneurons in vivo via dual targeting. Mol. Pharm., 2013, 10 (11), 4195-206.
135. [135] Sutton, J.M.; Wayne, J.; Scott-Tucker, A.; O'Brien, S.M.; Marks, P.M.; Alexander, F.C.; Shone, C.C.; Chaddock, J.A. Preparation of specifically activatable endopeptidase derivatives of Clostridium botulinum toxins type A, B, and C and their applications. Pro. Expr. Purif., 2005, 40 (1), 31-41.
136. [136] Band, P.A.; Blais, S.; Neubert, T.A.; Cardozo, T.J.; Ichtchenko, K. Recombinant derivatives of botulinum neurotoxin A engineered for trafficking studies and neuronal delivery. Pro. Expr. Purif., 2010, 71 (1), 62-73.
137. [137] Edupuganti, O.P.; Ovsepian, S.V.; Wang, J.; Zurawski, T.H.; Schmidt, J.J.; Smith, L.; Lawrence, G.W.; Dolly, J.O. Targeted delivery into motor nerve terminals of inhibitors for SNAREcleaving proteases via liposomes coupled to an atoxic botulinum neurotoxin. J. FEBS, 2012, 279 (14), 2555-67.
138. [138] Wang, J.; Zurawski, T.H.; Meng, J.; Lawrence, G.W.; Aoki, K.R.; Wheeler, L.; Dolly, J.O. Novel chimeras of botulinum and tetanus neurotoxins yield insights into their distinct sites of neuroparalysis. J. FASEB, 2012, 26 (12), 5035-48.
139. [139] Goodnough, M.C.; Oyler, G.; Fishman, P.S.; Johnson, E.A.; Neale, E.A.; Keller, J.E.; Tepp, W.H.; Clark, M.; Hartz, S.; Adler, M. Development of a delivery vehicle for intracellular transport of botulinum neurotoxin antagonists. FEBS, Lett., 2002, 513 (2-3), 163-8.
140. [140] Ho, M.; Chang, L.H.; Pires-Alves, M.; Thyagarajan, B.; Bloom, J.E.; Gu, Z.; Aberle, K.K.; Teymorian, S.A.; Bannai, Y.; Johnson, S.C.; McArdle, J.J.; Wilson, B.A. Recombinant botulinum neurotoxin A heavy chain-based delivery vehicles for neuronal cell targeting. Pro. Eng. Des. Sel., 2011, 24 (3), 247-53.
141. [141] McNaughton, B.R.; Cronican, J.J.; Thompson, D.B.; Liu, D.R. Mammalian cell penetration, siRNA transfection, and DNA transfection by supercharged proteins. Proc. Natl. Acad. Sci. U S A, 2009,106 (15), 6111-6.
142. [142] Krautz-Peterson, G.; Zhang, Y.; Chen, K.; Oyler, G.A.; Feng, H.; Shoemaker, C.B. Retargeting Clostridium difficile Toxin B to neuronal cells as a potential vehicle for cytosolic delivery of therapeutic biomolecules to treat botulism. J. Toxicol., 2012, 2012, 760142.
143. [143] Johannes, L.; Popoff, V. Tracing the retrograde route in protein trafficking. Cell, 2008, 135 (7), 1175-87.
144. [144] Morlon-Guyot, J.; Mere, J.; Bonhoure, A.; Beaumelle, B. Processing of Pseudomonas aeruginosa exotoxin A is dispensable for cell intoxication. Infect. Immun., 2009, 77 (7), 3090-9.
145. [145] Spooner, R.A.; Smith, D.C.; Easton, A.J.; Roberts, L.M.; Lord, J.M. Retrograde transport pathways utilised by viruses and protein toxins. J. Virol., 2006, 3, 26.
146. [146] Hessler, J.L.; Kreitman, R.J. An early step in Pseudomonas exotoxin action is removal of the terminal lysine residue, which allows binding to the KDEL receptor. Biochemistry, 1997, 36 (47), 14577-82.
147. [148] Guimaraes, C.P.; Carette, J.E.; Varadarajan, M.; Antos, J.; Popp, M.W.; Spooner, E.; Brummelkamp, T.R.; Ploegh, H.L. Identification of host cell factors required for intoxication through use of modified cholera toxin. J. Cell Biol., 2011, 195 (5), 751-64.
148. [149] Aurisicchio, L.; Peruzzi, D.; Koo, G.; Wei, W. Z.; La Monica, N.; Ciliberto, G. Immunogenicity and therapeutic efficacy of a dualcomponent genetic cancer vaccine cotargeting carcinoembryonic antigen and HER2/neu in preclinical models. Hum. Gene. Ther., 2014, 25 (2), 121-31.
149. [150] Facciabene, A.; Aurisicchio, L.; Elia, L.; Palombo, F.; Mennuni, C.; Ciliberto, G.; La Monica, N. Vectors encoding carcinoembryonic antigen fused to the B subunit of heat-labile enterotoxin elicit antigen-specific immune responses and antitumor effects. Vaccine, 2007, 26 (1), 47-58.
150. [151] Boberg, A.; Gaunitz, S.; Brave, A.; Wahren, B.; Carlin, N. Enhancement of epitope-specific cellular immune responses by immunization with HIV-1 peptides genetically conjugated to the Bsubunit of recombinant cholera toxin. Vaccine, 2008, 26 (40), 5079-82.
151. [152] Sun, J.B.; Flach, C.F.; Czerkinsky, C.; Holmgren, J.B. lymphocytes promote expansion of regulatory T cells in oral tolerance: Powerful induction by antigen coupled to cholera toxin B subunit. J. Immunol., 2008, 181 (12), 8278-87.
152. [153] Berntsson, R.P.; Peng, L.; Dong, M.; Stenmark, P. Structure of dual receptor binding to botulinum neurotoxin B. Nat. Commun., 2013, 4, 2058.
153. [154] Ahnert-Hilger, G.; Munster-Wandowski, A.; Holtje, M., Synaptic vesicle proteins: Targets and routes for botulinum neurotoxins. Curr. Top. Microbiol. Immunol., 2013, 364, 159-77.
154. [155] Brunger, A.T.; Rummel, A. Receptor and substrate interactions of clostridial neurotoxins. Toxicon, 2009, 54 (5), 550-60.
155. [156] Torres Demichelis, V.; Vilcaes, A.A.; Iglesias-Bartolome, R.; Ruggiero, F.M.; Daniotti, J.L. Targeted delivery of immunotoxin by antibody to ganglioside GD3: A novel drug delivery route for tumor cells. PLoS One, 2013, 8 (1), e55304.
156. [157] Pastan, I.; Hassan, R.; Fitzgerald, D.J.; Kreitman, R.J. Immunotoxin therapy of cancer. Nat. Rev. Cancer, 2006, 6 (7), 559-65.
157. [158] Knechtle, S.J. Treatment with immunotoxin. Philosophical transactions of the Royal Society of London. Series B, Biol. Sci., 2001, 356 (1409), 681-9.
158. [159] Chari, R.V.; Miller, M.L.; Widdison, W.C. Antibody-drug conjugates: An emerging concept in cancer therapy. Angew. Chem. Int. Ed. Engl., 2014, 53 (15), 3796-827.
159. [160] Panowksi, S.; Bhakta, S.; Raab, H.; Polakis, P.; Junutula, J.R. Sitespecific antibody drug conjugates for cancer therapy. MABS, 2014, 6 (1), 34-45.